Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid

Kong, X; Strauss, RW; Michaelides, M; Cideciyan, AV; Sahel, JA; Muñoz, B; West, S; Scholl, HP; ProgStar Study Group.
Visual Acuity Loss and Associated Risk Factors in the Retrospective Progression of Stargardt Disease Study (ProgStar Report No. 2).
Ophthalmology. 2016; 123(9):1887-1897
Web of Science PubMed FullText FullText_MUG

 

Autor/innen der Med Uni Graz:
Strauß Rupert
Altmetrics:

Dimensions Citations:

Plum Analytics:
Abstract:
To examine the association between characteristics of Stargardt disease and visual acuity (VA), to estimate the longitudinal rate of VA loss, and to identify risk factors for VA loss. Retrospective, multicenter cohort study. A total of 176 patients (332 eyes) with molecularly and clinically confirmed Stargardt disease enrolled from the United States and Europe. Standardized data report forms were used to collect retrospective data on participants' characteristics and best-corrected or presenting VA from medical charts. Linear models with generalized estimating equations were used to estimate the cross-sectional associations, and linear mixed effects models were used to estimate the longitudinal VA loss. Yearly change in VA. The median duration of observation was 3.6 years. At baseline, older age of symptom onset was associated with better VA, and a longer duration of symptoms was associated with worse VA. Longitudinal analysis estimated an average of 0.3 lines loss (P < 0.0001) per year overall, but the rate varied according to baseline VA: (1) eyes with baseline VA ≥20/25 (N = 53) declined at a rate of approximately 1.0 line per year; (2) eyes with VA between 20/25 and 20/70 (N = 65) declined at a rate of approximately 0.9 lines per year; (3) eyes with VA between 20/70 and 20/200 (N = 163) declined at a rate of 0.2 lines per year; and (4) eyes with VA worse than 20/200 (n = 49) improved at a rate of 0.5 lines per year. Older age of onset was associated with slower VA loss: Patients with onset age >30 years showed 0.4 lines slower change of VA per year (P = 0.01) compared with patients with onset age ≤14 years. Given the overall slow rate of VA loss, VA is unlikely to be a sensitive outcome measure for treatment trials of Stargardt disease. However, given the faster decline in younger patients and those with no or mild visual impairment, VA may be a potential outcome measure for trials targeting such subgroups of patients. These observations will need to be assessed in a prospective study bearing in mind the inherent limitations of retrospective datasets. Copyright © 2016 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.
Find related publications in this database (using NLM MeSH Indexing)
Adolescent -
Adult -
Age of Onset -
Aged -
Child -
Cross-Sectional Studies -
Disease Progression -
Europe -
Humans -
Linear Models -
Macular Degeneration - complications
Macular Degeneration - congenital
Macular Degeneration - physiopathology
Male -
Middle Aged -
Retrospective Studies -
Risk Factors -
United States -
Vision Disorders - etiology
Vision Disorders - physiopathology
Visual Acuity -
Young Adult -

© Meduni Graz Impressum